Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 3/20 | 0.65 |
| ▸ | ECE1 | P42892 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oglufanide SCHEMBL3053743 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5822555 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5735529 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5822559 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL2042188 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL24454642 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL1898073 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL27879986 | 0.99 | ERAP2 (0.67) | ERAP2ACEECE1KDM4EMEN1 | |
| SCHEMBL31483276 | 0.98 | ERAP2 (0.69) | ERAP2ACEECE1KDM4EMEN1 | |
| SCHEMBL29603192 | 0.95 | ERAP2 (0.66) | ERAP2ACEECE1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012068412-A2 | METHOD AND COMPOSITIONS FOR TREATMENT OF STAT3-RESPONSIVE CANCERS AND/OR RENAL CANCER | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | claimed |
| EP-1814566-B1 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2010-07-28 | — | — | EP | claimed |
| WO-1998009989-A1 | THE USE OF MURAMYLPEPTIDES IN THE TREATMENT OF MYELOSUPPRESSED OR OTHERWISE IMMUNOCOMPROMISED STATES | PEPTECH (UK) LIMITED (GB) | 1998-03-12 | — | — | WO | claimed |
| EP-0722332-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1995010293-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1995-04-20 | — | — | WO | claimed |
| CN-103502215-A | Prodrugs of D-gamma-glutamyl-D-tryptophan and D-gamma-glutamyl-L-tryptophan | APOTEX TECHNOLOGIES INC | 2014-01-08 | — | — | CN | disclosed |
| WO-2013155592-A1 | CRYSTAL FORMS OF GOLOTIMOD AND PROCESS FOR ITS MANUFACTURING | APOTEX TECHNOLOGIES INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013155595-A1 | PROCESS FOR THE PREPARATION OF A MONOSODIUM SALT OF H-D-GLU-(L-TRP-OH)-OH AND A CRYSTALLINE FORM THEREOF | APOTEX TECHNOLOGIES INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013123574-A1 | ORALLY BIOAVAILABLE DERIVATIVES OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2013-08-29 | — | — | WO | disclosed |
| WO-2012068412-A2 | METHOD AND COMPOSITIONS FOR TREATMENT OF STAT3-RESPONSIVE CANCERS AND/OR RENAL CANCER | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2323979-A1 | TREATMENT OR PREVENTION OF HEPATITIS C WITH IMMUNOMODULATOR COMPOUNDS | SciClone Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2192835-A1 | TREATMENT OF LUNG CANCER | Sciclone Pharmaceuticals, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1814566-A2 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SciClone Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1420808-A4 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006047702-A2 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-1420808-A1 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | Sciclone Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003013572-A1 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-1042286-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | Wei, Edward T. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033799-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI EDWARD T (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1997019691-A1 | GAMMA-L-GLUTAMYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI, EDWARD, T. (US) | 1997-06-05 | — | — | WO | disclosed |